About imugene - IUGNF
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
IUGNF At a Glance
Imugene Ltd.
4-6 Bligh Street
Sydney, New South Wales (NSW) 2000
| Phone | N/A | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -44,700,534.87 | |
| Sector | Health Technology | Employees | 23 | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
IUGNF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.156 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.216 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.125 |
IUGNF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,943,501.516 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IUGNF Liquidity
| Current Ratio | 1.885 |
| Quick Ratio | 1.732 |
| Cash Ratio | 0.99 |
IUGNF Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -57.349 |
| Return on Equity | -82.406 |
| Return on Total Capital | -122.493 |
| Return on Invested Capital | -80.706 |
IUGNF Capital Structure
| Total Debt to Total Equity | 23.653 |
| Total Debt to Total Capital | 19.128 |
| Total Debt to Total Assets | 12.743 |
| Long-Term Debt to Equity | 6.31 |
| Long-Term Debt to Total Capital | 5.103 |